HIV tropism testing (see Policy Guidelines section for testing methods) may be considered medically necessary for selecting patients for treatment with HIV coreceptor antagonists, such as maraviroc, when there is an immediate plan to prescribe a coreceptor antagonist.
HIV tropism testing without immediate plans to prescribe HIV coreceptor antagonists such as maraviroc is not medically necessary.
Repeat HIV tropism testing during coreceptor antagonist treatment or after failure with coreceptor antagonists is investigational.
HIV tropism testing to predict disease progression (irrespective of coreceptor antagonist treatment) is investigational.
